Radioactive antibody hunt: could a new scan outsmart hidden kidney cancer?

NCT ID NCT06447103

Recruiting now Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase II trial tests whether a special PET/CT scan using a radioactive tracer called 89Zr-DFO-girentuximab can find recurrent clear cell renal cell carcinoma after surgery better than standard contrast-enhanced CT. The tracer attaches to a protein (CAIX) on kidney cancer cells, making them visible on the scan. About 91 adults who had surgery for kidney cancer will be enrolled to compare the two imaging methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-DFO-girentuximab (a radioactive tracer that attaches to CAIX protein on kidney cancer cells)
What this could lead to: If successful, this imaging method could detect recurrent kidney cancer earlier and more accurately than standard CT scans, potentially improving treatment decisions.
What could go wrong: This is a Phase II trial with only 91 participants, so results may not apply to all patients. The new tracer involves radiation exposure and may not detect all recurrences.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nonpapillary renal cell carcinoma renal cell adenocarcinoma renal cell carcinoma sarcomatoid renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA SARCOMATOID RENAL CELL CARCINOMA STAGE II RENAL CELL CANCER STAGE III RENAL CELL CANCER STAGE IV RENAL CELL CANCER

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.